StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics, Inc grew revenue 34.8% to $281.99M over the twelve months to Jun 30, 2026. Operating income rose 143.3% to $58.34M, moving the operating margin from 11.5% to 20.7%. Free cash flow was $130.58M, up 252.0% from a year earlier. At the latest close the market valued the company at $8.07B, 121.0 times its earnings.

Revenue
$281.99M
+34.8% vs. a year earlier
Operating income
$58.34M
+143.3% vs. a year earlier
Free cash flow
$130.58M
+252.0% vs. a year earlier
EPS, diluted
$1.03
+47.1% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$8.07B
P/E ratio
121.0
Price to sales
28.61
Price to book
9.59
Dividend yield
–
Free cash flow yield
1.62%

Fundamentals

Revenue
$281.99M
Net income
$82.91M
EPS, diluted
$1.03
Free cash flow
$130.58M
Book value per share
$11.85
Diluted shares
71M

Trading

Next earnings
Feb 24, 2027 (estimated, after the close)
Previous close
$124.83
Open
$124.65
Day's range
$121.75 – $125.90
Volume
583,078
Average volume (20 days)
593,761
Index membership
S&P SmallCap 600 (since Aug 2024), Russell 2000, Russell 3000
52-week range
$77.00 – $160.81
RSI (14 days)
32.5
Volatility (1 year)
40.3%
Relative volume
0.93×

On 1 of our idea list: Most shorted (a warning list)

Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2016, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodPTGXS&P 500DifferencePTGX per yearS&P 500 per year
1 month-3.2%-4.0%+0.9 pts
3 months-21.4%-5.0%−16.4 pts
Year to date+42.7%+8.2%+34.5 pts
1 year+47.1%+11.2%+35.9 pts
3 years+641.6%+68.5%+573.2 pts+95.0%+19.0%
5 years+242.3%+67.3%+175.0 pts+27.9%+10.8%
10 years+398.9%+291.6%+107.2 pts+17.4%+14.6%

Thirteen years at a glance

Fiscal years 2013 to 2025 and trailing twelve months, USD

Revenue

$281.99M+34.8% YoY

Operating income

$58.34M+143.3% YoY

Net income

$82.91M+59.3% YoY

EPS, diluted

$1.03+47.1% YoY

Free cash flow

$130.58M+252.0% YoY
Reported periodTrailing twelve months

Press releases

Releases Protagonist Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Protagonist Therapeutics

Pharmaceutical Preparations

Protagonist Therapeutics is an integrated biopharmaceutical company focused on discovering and developing differentiated peptide-based medicines. The company organizes its research across three core therapeutic segments: inflammation and immunology, hematology, and metabolic diseases. Key development-stage assets include icotrokinra for plaque psoriasis, rusfertide for polycythemia vera, and preclinical candidates targeting obesity and related conditions. Operating primarily through strategic partnerships, Protagonist collaborates with major multinational pharmaceutical corporations such as Janssen Biotech and Takeda Pharmaceuticals for Phase 2 and Phase 3 development, regulatory submissions, and commercialization.

Company profile, executives and history

Protagonist Therapeutics stock: common questions

What is Protagonist Therapeutics's stock price?

PTGX closed at $124.67 on Nov 17, 2026, down 0.13% on the day. Over the past 52 weeks it traded between $77.00 and $160.81.

What is Protagonist Therapeutics's market cap?

Protagonist Therapeutics was worth $8.07B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is PTGX's P/E ratio?

PTGX trades at 121.0 times earnings, based on diluted earnings per share of $1.03 over the twelve months to Jun 30, 2026.

How much revenue does Protagonist Therapeutics make?

Protagonist Therapeutics reported revenue of $281.99M for the twelve months to Jun 30, 2026, up 34.8% from a year earlier.

Does Protagonist Therapeutics pay a dividend?

No. Protagonist Therapeutics has not paid a cash dividend over the last twelve months.

When does Protagonist Therapeutics report earnings next?

Protagonist Therapeutics is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has PTGX stock performed over the past year?

Including dividends, PTGX returned +47.1% over the past year, against +11.2% for the S&P 500.

How many PTGX shares are sold short?

10M shares were sold short at the latest FINRA report, 16.09% of the float, or 16.9 days of average trading volume.

Who are Protagonist Therapeutics's competitors?

Companies most similar to Protagonist Therapeutics by business, industry and size include NRIX, EVO, RARE, HCM, AAPG.

See a number that looks wrong?